甲酶响应纳米颗粒的向输送用于治疗糖尿病炎症
Nathan Schiffmann1, Yifei Liang2, Carlos E Nemcovsky3
1Department of Oral Biology, The Maurice and Gabriela Goldschleger School of Dental Medicine, Faculty of Medicine, and The Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 6997801, Israel.
Advanced healthcare materials
|July 27, 2023
概括
酶响应纳米颗粒有效地输送了德克萨米他,以减少糖尿病老鼠的炎症,通过向受影响的组织改善伤口愈合,并提高治疗结果.
科学领域:
- 生物材料科学 生物材料科学
- 纳米医学是一种纳米医学.
- 糖尿病伤口愈合 糖尿病伤口愈合
背景情况:
- 糖尿病是一种全球性健康危机,与伤口愈合受损和感染风险增加有关.
- 目前用于糖尿病伤口的治疗方法往往缺乏向性治疗,导致效果不佳.
- 需要新的治疗策略来增强药物输送到糖尿病伤口.
研究的目的:
- 开发和评估酶响应纳米颗粒,以有针对性地将甲输送到炎症的糖尿病组织中.
- 在糖尿病老鼠模型中评估这些纳米颗粒在减少炎症和促进伤口愈合方面的有效性.
主要方法:
- 用光标记的,装有德克萨米他的-聚合物合物被合成成对酶有反应的纳米粒子.
- 纳米粒子在体内与糖尿病大鼠植入的原体膜相邻地被施用.
- 在纳米颗粒治疗和对照组中量化了原体膜再吸收和炎症细胞透.
主要成果:
- 响应性纳米粒子在炎症组织中长时间积累,形成微观聚合物.
- 用响应性纳米颗粒治疗的老鼠表现出明显更大的剩余原膜面积.
- 与对照组相比,在纳米粒子治疗的老鼠中观察到减少了炎症细胞透.
结论:
- 酶响应纳米颗粒显示出作为针对糖尿病伤口治疗中抗炎药物的向输送系统的前景.
- 这种方法通过将药物集中在炎症部位上来提高治疗效果.
- 进一步研究基于纳米粒子的疗法可能会彻底改变糖尿病和其他炎症性伤口的管理.
更多相关视频
相关概念视频
Drug Delivery: Miscellaneous Routes
383
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
383
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Insulin: Dosing Regimen and Adverse Effects
211
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
211
Diabetes: Management and Pharmacotherapy
317
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
317
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K


